Sydney-based life sciences investor Proto Axiom has signed its second investment out of the University of NSW, backing a fertility biotech that’s trying to improve IVF success rates for patients 35 and older.
In vitro fertilisation success rates sharply decline from age 35 onwards, JumpStart Fertility says. Istock
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
